Structural and functional characterization of β 2 ‐glycoprotein I domain 1 in anti‐melanoma cell migration
Autor: | Kai Yao Huang, Tzong Yi Lee, Meng Ying Tsai, Shr Jeng Jim Leu, An-Na Chiang, Shu Wei Cheng, Yu-Shan Lin, Tzeon Jye Chiou |
---|---|
Rok vydání: | 2019 |
Předmět: |
0301 basic medicine
chemistry.chemical_classification Cancer Research medicine.diagnostic_test Chemistry Immunoprecipitation Cell migration General Medicine Molecular biology Amino acid law.invention 03 medical and health sciences 030104 developmental biology 0302 clinical medicine Oncology Western blot law 030220 oncology & carcinogenesis Complementary DNA medicine Recombinant DNA Peptide sequence Annexin A2 |
Zdroj: | Cancer Science. 110:1974-1986 |
ISSN: | 1349-7006 1347-9032 |
DOI: | 10.1111/cas.14030 |
Popis: | We previously found that circulating β2 -glycoprotein I inhibits human endothelial cell migration, proliferation, and angiogenesis by diverse mechanisms. In the present study, we investigated the antitumor activities of β2 -glycoprotein I using structure-function analysis and mapped the critical region within the β2 -glycoprotein I peptide sequence that mediates anticancer effects. We constructed recombinant cDNA and purified different β2 -glycoprotein I polypeptide domains using a baculovirus expression system. We found that purified β2 -glycoprotein I, as well as recombinant β2 -glycoprotein I full-length (D12345), polypeptide domains I-IV (D1234), and polypeptide domain I (D1) significantly inhibited melanoma cell migration, proliferation and invasion. Western blot analyses were used to determine the dysregulated expression of proteins essential for intracellular signaling pathways in B16-F10 treated with β2 -glycoprotein I and variant recombinant polypeptides. Using a melanoma mouse model, we found that D1 polypeptide showed stronger potency in suppressing tumor growth. Structural analysis showed that fragments A and B within domain I would be the critical regions responsible for antitumor activity. Annexin A2 was identified as the counterpart molecule for β2 -glycoprotein I by immunofluorescence and coimmunoprecipitation assays. Interaction between specific amino acids of β2 -glycoprotein I D1 and annexin A2 was later evaluated by the molecular docking approach. Moreover, five amino acid residues were selected from fragments A and B for functional evaluation using site-directed mutagenesis, and P11A, M42A, and I55P mutations were shown to disrupt the anti-melanoma cell migration ability of β2 -glycoprotein I. This is the first study to show the therapeutic potential of β2 -glycoprotein I D1 in the treatment of melanoma progression. |
Databáze: | OpenAIRE |
Externí odkaz: |